Leflunomide for the successful management of juvenile Cogan's syndrome.
Cogan's syndrome (CS) is a rare multisystemic disorder characterized by inflammatory eye diseases and vestibuloauditory dysfunctions. It is prone to be misdiagnosed or overlooked, and the prognosis of those delayed-diagnosed CS is not optimistic. Despite isolated patient responses to systemic treatment including steroids and methotrexate, there is currently no general consensus on an effective treatment for CS. We present a case of Cogan's syndrome remission associated with leflunomide (LEF) in a juvenile patient. To date, there is no such report on CS, especially in children, which is successfully treated by LEF in combination with glucocorticoids.
Xie
Liyi
L
Department of Radiation Oncology, Cancer Hospital, Fudan University, Shanghai, China.
Cai
Yubo
Y
Bao
Xuhui
X
Cao
Lanfang
L
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001799:Blood Sedimentation; D002648:Child; D055952:Cogan Syndrome / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D000077339:Leflunomide; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use*; D012074:Remission Induction; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D007555:Isoxazoles; D011239:Prednisolone; D000077339:Leflunomide; D008775:Methylprednisolone